

# Key Priorities for FDA's Controlled Substances Program

Marta Sokolowska, PhD

Associate Director for Controlled Substances

Office of the Center Director/ CDER / FDA

# Controlled Substance Program: Overview

The **Controlled Substance Program (CSP)** aims to help CDER take a more proactive approach to limit problematic use while enabling appropriate access to controlled substances.

## CSP Mission



To promote the **public health** through strategic programs and policies to help **enable appropriate access** to controlled substances for medical use and identify, mitigate and manage emerging issues with controlled substances to **minimize risks associated with problematic use** of these products.



# CSP Core Functions

## Scientific Expertise



Provide consultation services and medical science-based assessment and management of drug abuse risks

## Identify and Analyze



Proactively identify emerging issues in controlled substances and related strategy and initiatives to drive appropriate access

## Manage and Influence



Effectively coordinate CDER/FDA controlled substances efforts and facilitating intra- and inter-agency interactions

## Rapid Response




Provide rapid response to internal and external inquiries related to controlled substances

## Strategic Engagement




Communicate with and engage stakeholders on emerging issues/ongoing activities (with internal strategic partners)

# CSP Stakeholders



*This is a non-exhaustive list of the internal and external stakeholders for CSP.*

# CSP Portfolio





# CSP and COVID-19

CSP is broadly working across CDER to assess the **public health consequences of COVID-19 on drug abuse**, as well as the potential actions that FDA can or should proactively take.



*Identify/  
Analyze*



*Strategic  
Engagement*



- ***What are you most concerned about regarding the potential impact of COVID-19 on substance abuse?***
- ***Who should CSP be engaging to better understand and prepare for the potential public health consequences of COVID-19 on substance abuse?***

Thank you

[Marta.Sokolowska@fda.hhs.gov](mailto:Marta.Sokolowska@fda.hhs.gov)